
Sign up to save your podcasts
Or


The FDA is expected to approve Tirzepatide for weight loss sometime this year and we think it could become the best selling drug of ALL TIME. Today on Dumb Money, we'll weigh the data, size-up the opportunity, and give you the skinny on our diet drug investment thesis.
Here are the GLP-1 RA drug makers and their drugs:
Eli Lilly (ticker LLY)
Tirzepatide sold as Mounjaro for diabetes. Weight loss version expected in 2023.
Dulaglutide sold as Trulicity.
Novo Nordisk (ticker NVO)
Semaglutide sold as Ozempic and Rybelsus for diabetes and Wegovy for weight loss.
Liraglutide sold as Victoza for diabetes and Saxenda for weight loss.
By Dumb Money4.7
110110 ratings
The FDA is expected to approve Tirzepatide for weight loss sometime this year and we think it could become the best selling drug of ALL TIME. Today on Dumb Money, we'll weigh the data, size-up the opportunity, and give you the skinny on our diet drug investment thesis.
Here are the GLP-1 RA drug makers and their drugs:
Eli Lilly (ticker LLY)
Tirzepatide sold as Mounjaro for diabetes. Weight loss version expected in 2023.
Dulaglutide sold as Trulicity.
Novo Nordisk (ticker NVO)
Semaglutide sold as Ozempic and Rybelsus for diabetes and Wegovy for weight loss.
Liraglutide sold as Victoza for diabetes and Saxenda for weight loss.

3,371 Listeners

1,994 Listeners

395 Listeners

1,834 Listeners

2,111 Listeners

357 Listeners

9,951 Listeners

774 Listeners

444 Listeners

135 Listeners

272 Listeners

554 Listeners

471 Listeners

29 Listeners

78 Listeners